Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential

Journal of Medicinal Chemistry

Volumn 35, Issue 3, 1992, Pages 407-422

  Jacobson, Kenneth A ^a   van Galen, Philip J M ^a   Williams, Michael ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CYCLOHEXYLETHOXY)ADENOSINE; 2 [(2 CYCLOHEXYLETHYL)AMINO]ADENOSINE; 2 [2 (2 CYCLOHEXENYL)ETHYLAMINO]ADENOSINE; 2 [2 (4 METHYLPHENYL)ETHOXY]ADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; 8 (3 NORADAMANTYL) 1,3 DIPROPYLXANTHINE; 8 (3 OXOCYCLOPENTYL) 1,3 DIPROPYLXANTHINE; ADENINE DERIVATIVE; ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; CAFFEINE; CGS 22492; CGS 22989; DIPYRIDAMOLE; DIURETIC AGENT; DRAFLAZINE; KFM 19; MIOFLAZINE; NOOTROPIC AGENT; PENTOXIFYLLINE; RECEPTOR SUBTYPE; THEOPHYLLINE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD BRAIN BARRIER; BRAIN; CATTLE; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STABILITY; GUINEA PIG; HUMAN; HUMAN CELL; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

ADENOSINE; ANIMAL; HUMAN; MODELS, CHEMICAL; RECEPTORS, PURINERGIC; SECOND MESSENGER SYSTEMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0026520040     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00081a001     Document Type: Article

References (171)

1. Daly, J. W. Adenosine receptors: targets for future drugs. J. Med. Chem. 1982, 25, 197-207.
2. Williams, M. Adenosine: the prototypic neuromodulator. Neurochem. Intern. 1989, 14, 249-264.
3. Libert, F.; Schiffmann, S.; Lefort, A.; Parmentier, M.; Gerard, C.; Dumont, J. E.; Vanderhaegen, J. J.; Vassart, G. The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. EMBO J. 1991, 10, 1677-1682.
4. Maenhaut, C.; van Sande, S. J.; Libert, F.; Abramowicz, M.; Parmentier, M.; Vanderhaegen, J. J.; Dumont, J. E.; Vassart, G.; Schiffmann, S. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem. Biophys. Res. Commun. 1990, 173, 1169-1178.
5. Hollenberg, M. D. Receptor triggering and receptor regulation: Structure-activity relationship from the receptor’s point of view. J. Med. Chem. 1990, 33, 1275-81.
6. Trivedi, B. K.; Bridges, A. J.; Bruns, R. F. Structure-activity relationships of adenosine Aj and A2 receptors. In Adenosine and Adenosine Receptors., Williams, M., Ed.; Humana: Clifton, NJ, 1990; pp 57-103.
7. Jacobson, K. A.; Trivedi, B. K.; Churchill, P. C.; Williams, M. Novel therapeutics acting via purine receptors. Biochem. Pharmacol. 1991, 41, 1399-1410.
8. Williams, M. Adenosine antagonists as therapeutic agents. Med. Res. Rev. 1989, 9, 219-43.
9. Pantely, G. A.; Bristow, J. D. Adenosine. Renewed interest in an old drug. Circulation 1990, 82, 1854-1856.
10. Verani, M. S.; Mahmanian, J. J.; Hixson, J. B.; Boyce, T. M.; Staudacher, R. A. Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium- 201 in patients unable to exercise. Circulation 1990, 82, 80-87.
11. Lasley, R. D.; Rhee, J. W.; Van Wylen, D. G. L.; Mentzer, R. M., Jr. Adenosine At receptor mediated protection of the globally ischemic isolated rat heart. J. Mol. Cell. Cardiol. 1990 22 39-47.
12. Pitarys, C. J., II; Virmani, R.; Vildibill, H. D.; Jackson, E. K.; Forman, M. B. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 1991, 83, 237-247.
13. Williams, M. Purinergic pharmaceuticals for the 1990s. Nucleosides Nucleotides 1991, 10, 1087-1089.
14. Drury, A. N.; Szent-Gyorgyi, A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. (Lond) 1929, 68, 213-237.
15. Honey, R. M.; Ritchie, W. T.; Thompson, W. A. R. The action of adenosine upon the human heart. Quart. J. Med. 1930, 23, 485-490.
16. Olsson, R. A.; Pearson, J. D. Cardiovascular purinoceptors. Physiol. Rev. 1990, 70, 761-845.
17. Hamprecht, B.; Van Calker, D. Trends Pharmacol. Sci. 1985, 6, 153-154.
18. Bruns, R. F.; Lu, G. H.; Pugsley, T. A. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol. Pharmacol. 1986, 29, 331-346.
19. Gustaffson, L. E.; Wiklund, C. U.; Wiklund, N. P.; Stelius, L. Subclassification of neuronal adenosine receptors. In Purines in Cellular Signaling. Targets for New Drugs; Jacobson, K. A., Daly, J. W., Manganiello, V., Eds.; Springer Verlag: New York, 1990; pp 200-205.
20. Ribeiro, J. A.; Sebastião, A. M. Adenosine receptors and calcium: basis for proposing a third (A3) adenosine receptor. Prog. Neurobiol. 1986, 26, 179-209.
21. Ferkany, J. W.; Valentine, H. L.; Stone, G. A.; Williams, M. Adenosine Ax receptors in mammalian brain: species differences in their interactions with agonists and antagonists. Drug Dev. Res. 1986, 9, 85-93.
22. Stone, G. A.; Jarvis, M. F.; Sills, M. A.; Weeks, B.; Snowhill, E. W.; Williams, M. Species differences in high-affinity adenosine A2 binding sites in striatal membranes from mammalian brain. Drug Dev. Res. 1988, 15, 31-46.
23. Weiner, H. L.; Craddock-Royal, B.; Maaynai, S. Tentative subclassification of the adenosine Al (AD Al) receptor in mammalian hippocampus. Abstr. Soc. Neurosci. 1990, 16, 33-38.
24. Bazil, C. W.; Minneman, K. P. An investigation of the low intrinsic activity of adenosine and its analogs at low affinity (A2) adenosine receptors in rat cerebral cortex. J. Neurochem. 1986, 47, 547-553.
25. Lohse, M.; Klotz, K. N.; Schwabe, U. Mechanism of A2 adenosine receptor activation. I. Blockade of A2 adenosine receptors by photoaffinity labeling. Mol. Pharmacol. 1991, 39, 517-523.
26. Lohse, M. J.; Klotz, K. N.; Schwabe, U.; Cristalli, G.; Vittori, S.; Grifantini, M. 2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn Schmiedebergs' Arch. Pharmacol. 1988, 337, 687-689.
27. van Galen, P. J. M.; Leusen, F. J. J.; IJzerman, A. P.; Soudijn, W. Mapping the N6-region of the adenosine Ax receptor with computer graphics. Eur. J. Pharmacol.-Mol. Pharmacol. Sect. 1989, 172, 19-27.
28. Taylor, M. D.; Moos, W. H.; Hamilton, H. W.; Szotek, D. S.; Patt, W. C.; Badger, E. W.; Bristol, J. A.; Bruns, R. F.; Heffner, T. G.; Mertz, T. E. Ribose-modified adenosine analogues as adenosine receptor agonists. J. Med. Chem. 1986, 29, 346-53.
29. Daly, J. W.; Padgett, W.; Thompson, R. D.; Kusachi, S.; Bugni, W. J.; Olsson, R. A. Structure-activity relationships for N6-substituted adenosines at a brain Ax-adenosine receptor with a comparison to an A2-adenosine receptor regulating coronary blood flow. Biochem. Pharmacol. 1986, 35, 2467-2481.
30. Trivedi, B. K. Structure-activity relationships for adenosine agonists. In Purines in Cellular Signaling. Targets for New Drugs; Jacobson, K. A., Daly, J. W., Manganiello, V., Eds.; Springer Verlag: New York, 1990; pp 136-145.
31. Ortwine, D. F.; Bridges, A. J.; Humblet, C.; Trivedi, B. K. Adenosine agonists. Characterization of the N6-region of the adenosine A2 receptor via molecular modeling techniques. In Purines in Cellular Signaling. Targets for New Drugs; Jacobson, K. A., Daly, J. W., Manganiello, V., Eds.; Springer Verlag: New York, 1990; pp 152-157.
32. Kawazoe, K.; Matsumato, M.; Tanabe, S.; Fujiwara, M.; Yanagimoto, M.; Hirata, M.; Kakiuchi, K. Coronary and cardiohemodynamic effects of 2-phenyl-aminoadenosine (CV1808) in anaesthetized dogs and cats. Arzneim. Forsch. 1980, 30, 1083-1087.
33. Hutchison, A. J.; Williams, M.; de Jesus, R.; Yokoyama, R.; Oei, H. H.; Ghai, G. R.; Webb, R. L.; Zoganas, H. C.; Stone, G. A.; Jarvis, M. F. 2-(Arylalkylamino)adenosin-5’- uronamides: a new class of highly selective adenosine A2 receptor ligands. J. Med. Chem. 1990, 33, 1919-1924.
34. Francis, J. E.; Webb, R. L.; Ghai, G. R.; Hutchison, A. J.; Moskal, M. A.; de Jesus, R.; Yokoyama, R.; Rovinski, S. L.; Contrado, N.; Dotson, R.; Barclay, B.; Stone, G. A.; Jarvis, M. F. Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines. J. Med. Chem. 1991, 34, 2570-2579.
35. Barrington, W. W.; Jacobson, K. A.; Hutchison, A. J.; Williams, M.; Stiles, G. L. Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6572-6576.
36. Jarvis, M. F.; Schulz, R.; Hutchison, A. J.; Do, U. H.; Sills, M. A.; Williams, M. [3H] CGS 21680, a selective A2-adenosine receptor agonist ligand directly labels A2-receptors in rat brain. J. Pharmacol. Exp. Ther. 1989, 251, 888-893.
37. Ueeda, M.; Thompson, R. D.; Arroyo, L. H.; Olsson, R. A. 2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor. J. Med. Chem. 1991, 34, 1334-1339.
38. Ueeda, M.; Thompson, R. D.; Arroyo, L. H.; Olsson, R. A. 2-Aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor. J. Med. Chem. 1991, 34, 1340-1344.
39. Ueeda, M.; Thompson, R. D.; Padgett, W. L.; Secunda, S.; Daly, J. W.; Olsson, R. A. Cardiovascular actions of adenosines, but not adenosine receptors, differ in rat and guinea pig. Life Sci. 1991, 49, 1351-1358.
40. Abiru, T.; Yamaguchi, T.; Watanabe, Y.; Kogi, K.; Aihara, K.; Matsuda, A. The antihypertensive effect of 2-alkynyladenoeines and their selective affinity for adenosine A2-receptors. Eur. J. Pharmacol. 1991, 196, 69-76.
41. Hutchison, A. J.; Webb, R. L.; Oei, H. H.; Ghai, G. R.; Zimmerman, M. B.; Williams, M. CGS 21680C, an A2 selective adenosine agonist with selective hypotensive activity. J. Pharmacol. Exp. Ther. 1989, 251, 47-55.
42. Black, J. W. Should we be concerned about the state of hormone receptor classification? In Perspectives on Receptor Classification; Black, J. W., Jenkinson, D. H., Gerskowitch, V. P., Eds.; Liss: New York, 1987; pp 11-15.
43. Daly, J. W.; Padgett, W. L. Agonist activity of 2- and 5’- substituted adenosine analogs and their N8-cycloalkyl derivatives at Ax- and A2-adenosine receptors coupled to adenylate cyclase. Biochem. Pharmacol. 1992, in press.
44. Cristalli, G.; Franchetti, P.; Grifantini, M.; Vittori, S.; Klotz, K. N.; Lohse, M. J. Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J. Med. Chem. 1988, 31, 1179-1183.
45. Sattin, A.; Rail, T. W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3’,5’-phosphate content of guinea pig cerebral slices. Mol. Pharmacol. 1970, 6, 13-23.
46. Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.; Hyun, J. L.; et al. Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J. Med. Chem. 1988, 31, 1014-20.
47. Trivedi, B. K.; Bruns, R. F. [1,2,4]-Triazolo[4,3-a]- quinoxalin-4-amines: a new class of At receptor selective adenosine antagonists. J. Med. Chem. 1988, 31, 1011-1014.
48. Sarges, R.; Howard, H. R.; Browne, R. G.; Lebel, L. A.; Seymour, P. A.; Koe, B. K. 4-Amino[1,2,4]triazolo[4,3-a]- quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J. Med. Chem. 1990, 33, 2240-2254.
49. van Galen, P. J. M.; Nissen, P.; van Wijngaarden, I.; IJzerman, A. P.; Soudijn, W. Iff-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J. Med. Chem. 1991, 34, 1202-1206.
50. Müller, C. E.; Hide, I.; Daly, J. W.; Rothenhäusler, K.; Eger, K. 7-Deaza-2-phenyladenines: structure-activity relationships of potent Ax selective adenosine receptor antagonists. J. Med. Chem. 1990, 33, 2822-2828.
51. Ukena, D.; Padgett, W. L.; Hong, O.; Daly, J. W.; Daly, D. T.; Olsson, R. A. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists. FEBS Lett. 1987, 215, 203-208.
52. May, J. M.; Martin, P. L.; Miller, J. R. N-0861: A selective Aradenosine receptor antagonist. FASEB J. 1991, 5, 1572.
53. Yang, Z.; Hon, P. M.; Chui, K. Y.; Xu, Z. L.; Chang, H. M.; Lee, C. M.; Cui, Y. X.; Wong, H.; Poon, C. D.; Fung, B. M. Naturally occurring benzofuran: isolation, structure elucidation and total synthesis of 5-(3-Hydroxypropyl)-7-methoxy- 2-(3’-methoxy-4’-hydroxyphenyl)-3-Benzo[b]furancarbaldehyde, a novel adenosine-Ax receptor ligand isolated from Salvia Militorrhiza bunge (Danshen). Tetrahedron Lett. 1991, 32, 2061-2064.
54. Daly, J. W. Adenosine agonists and antagonists. In Purines in Cellular Signaling. Targets for New Drugs; Jacobson, K. A., Daly, J. W., Manganiello, V., Eds.; Springer Verlag: New York, 1990; pp 3-12.
55. Patel, A.; Craig, R. H.; Daluge, S. M.; Linden, J. 125I-BWA844U, an antagonist radioligand with high affinity and selectivity for adenosine Ax receptors, and 126I-azido-BWA844U, a photoaffinity label. Mol. Pharmacol. 1988, 33, 585-591.
56. Bruns, R. F.; Fergus, J. H.; Badger, E. W.; Bristol, J. A.; Santay, L. A.; Hartman, J. D.; Hays, S. J.; Huang, C. C. Binding of the Ax-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn-Schmiedberg'ss Arch. Pharmacol. 1987, 335, 59-63.
57. Bruns, R. F. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem. Pharmacol. 1981, 30, 325-333.
58. Schwabe, U.; Ukena, D.; Lohse, M. J. Xanthine derivatives as antagonists at Ax and A2 adenosine receptors. Naunyn Schmiedebergs’ Arch. Pharmacol. 1985, 330, 212-221.
59. Schneller, S. W.; Ibay, A. C.; Christ, W. J.; Bruns, R. F. Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists. J. Med. Chem. 1989, 32, 2247-2254.
60. Daly, J. W.; Padgett, W. L.; Shamim, M. T. Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J. Med. Chem. 1986, 29, 1305-1308.
61. Bruns, R. F.; Davis, R. E.; Ninteman, F. W.; Poschel, B. P. H.; Wiley, J. N.; Heffner, T. G. Adenosine antagonists as pharmacological tools. In Adenosine and Adenine Nucleotides. Physiology and Pharmacology, Paton, D. M., Ed.; Taylor & Francis: London, 1988; pp 39-49.
62. Jacobson, K. A.; Kirk, K. L.; Padgett, W. L.; Daly, J. W. Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J. Med. Chem. 1985, 28, 1334-1340.
63. Jacobson, K. A.; Kirk, K. L.; Padgett, W. L.; Daly, J. W. A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. Mol. Pharmacol. 1986, 29, 26-133.
64. Daly, J. W.; Padgett, W.; Shamim, M. T.; Butts, L. P.; Waters, J. 1,3-Dialkyl-8-(p-sulfophenyl)-xanthines: potent water-soluble antagonists for Ax- and A2-adenosine receptors. J. Med. Chem. 1985, 28, 487-492.
65. Shimada, J.; Suzuki, F.; Nonaka, H.; Karasawa, A.; Mizumoto, H.; Ohno, T.; Kubo, K.; Ishii, A. 8-(Dicyclopropylmethyl)- 1.3-dipropylxanthine: a potent and selective adenosine Ax antagonist with renal protective and diuretic activities. J. Med. Chem. 1991, 34, 466-469.
66. Katsushima, T.; Nieves, L.; Wells, J. N. Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors. J. Med. Chem. 1990, 33, 1906-1910.
67. Schingnitz, G.; Küfner-Mühl, U.; Ensinger, H.; Lehr, E.; Kuhn, F. J. Selective Ax-antagonists for treatment of cognitive deficits. Nucleosides Nucleotides 1991, 10, 1067-1076.
68. Suzuki, F.; Shimada, J.; Mizumoto, H.; Nonaka, H.; Ishii, A.; Karasawa, A.; Kubo, K. KW-3902: A potent and selective adenosine Ax antagonist with renal protective and diuretic activity. Book of Abstracts, National Meeting of the American Chemical Society, New York City, NY, Aug 25-30; American Chemical Society: Washington, DC, 1991; Abstract MEDI112.
69. Czernik, A. J.; Petrack, B.; Kalinsky, H. J.; Psychoyos, S.; Cash, W. D.; Tsai, C.; Rinehart, R. K.; Granat, F. R.; Lovell, R. A.; Brundish, D. E.; Wade, R. CGS 8216: receptor binding characteristics of a potent benzodiazepine antagonist. Life Sci. 1982, 30, 363-372.
70. Peet, N. P.; Lentz, N. L.; Meng, E. C.; Dudley, M. W.; Ogden, A. M.; Demeter, D. A.; Weintraub, H. J.; Bey, P. A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors. J. Med. Chem. 1990, 33, 3127-3130.
71. Bruns, R. F.; Fergus, J. H. Solubilities of adenosine antagonists determined by radioreceptor assay. J. Pharm. Pharmacol. 1989, 41, 590-594.
72. Plagemann, P. G. W.; Wohlhuter, R. M. Permeation of nucleosides, nucleic acid bases and nucleotides in animal cells. Curr. Top. Membr. Trans. 1980, 14, 225-330.
73. Jarvis, S. M. Kinetic and molecular properties of nucleoside transporters in animal cells. In Topics and Perspectives in Adenosine Research; Gerlach, E., Becker, B. F., Eds.; Springer Verlag: Berlin, 1987; pp 102-117.
74. Wiley, J. S.; Brocklebank, A. M.; Snook, M. B.; Jamieson, G. P.; Sawyer, W. H.; Craik, J. D.; Cass, C. E.; Robins, M. J.; McAdam, D. P.; Paterson, A. R. A new fluorescent probe for the equilibrative inhibitor-sensitive nucleoside transporter. 5’-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5’-thioadenosine (SAENTA)-chi 2-fluorescein. Biochem. J. 1991, 273, 667-672.
75. Bruns, R. F.; Fergus, J. H. Allosteric enhancement of adenosine Ax receptor binding and function by 2-amino-3- benzoylthiophenes. Mol. Pharmacol. 1990, 38, 939-949.
76. Bruns, R. F.; Fergus, J. H.; Coughenour, L. L.; Courtland, G. G.; Pugsley, T. A.; Dodd, J. H.; Tinney, F. J. Structure-activity relationships for enhancement of adenosine Ax receptor binding by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 1990, 38, 950-958.
77. Gruber, H. A.; Hoffer, M. E.; McAllister, D. R.; Laikind, P. K.; Lane, T. A.; Schmid-Schoenbein, G. W.; Engler, R. L. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation 1989, 80, 1400-1411.
78. Barraco, R. A.; El-Ridi, M. R.; Parizon, M. The adenosine analog 5’-N-ethylcarboxamido adenosine, exerts mixed agonist actions of cardiorespiratory parameters in the intact but not decerebrate rat following microinjections into the nucleus tractus solitarius. Brain Res. 1990, 530, 54-72.
79. Nikodijevic, O.; Sarges, R.; Daly, J. W.; Jacobson, K. A. Behavioral effects of Ax- and A2-selective adenosine agonists and antagonists; evidence for synergism and antagonism. J. Pharmacol. Exp. Ther. 1991, 259, 286-294.
80. Rubin, L.; Porter, S.; Horner, H.; Yednock, T. Blood-brain barrier model. Patent Pub. 1991, W091/05038.
81. IJzerman, A. P.; Thedinga, K. H.; Custers, A. F. C. M.; Hoos, B.; Van Belle, H. Inhibition of nucleoside transport by a new series of compounds related to lidoflazine and mioflazine. Eur. J. Pharmacol. 1989, 172, 273-281.
82. Rubin, L.; Porter, S.; Horner, H.; Yednock, T. Blood-brain barrier model. Patent Pub. 1991, W091/05038.
83. Janusz, C. A.; Bruns, R. F.; Berman, R. F. Functional activity of the adenosine binding enhancer, PD 81,723, in the in vitro hippocampal slice. Brain Res. 1992, in press.
84. Izquierdo, I.; Medina, J. H. GABAa receptor modulation of memory: the role of endogenous benzodiazepines. Trends Pharmacol. Sci. 1991, 12, 260-265.
85. Young, A. B.; Fagg, G. E. Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. Trends Pharmacol. Sci. 1990, 11, 126-133.
86. Gengia’s ischemia therapy, Arasine, in Phase III. Scrip 1991, 1630, 23.
87. Marion Merrell Dow to evaluate Gensia ARA compound. Scrip 1991, 1643, 12.
88. Agarwal, R. P. Adenosine deaminase. Measurement of activity and use of inhibitors. In Methods In Pharmacology. Vol. 6. Methods Used in Adenosine Research; Paton, D. M., Ed.; Plenum: New York, 1985; pp 109-125.
89. Phillis, J. W.; Walter, G. A.; Simpson, R. E. Brain adenosine and transmitter amino acid release from the ischemic rat cerebral cortex: effects of the adenosine deaminase inhibitor deoxycoformycin. J. Neurochem. 1991, 56, 644-650.
90. Cronstein, B. N.; Eberle, M. A.; Gruber, H. E.; Levin, R. I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2441-2445.
91. Cronstein, B. N.; Daguma, L.; Nichols, D.; Hutchison, A. J.; Williams, M. The adenosine/neutrophil paradox resolved: human neutrophils possess both A4 and A2 receptors that promote chemotaxis and inhibit O2~ generation, respectively. J. Clin. Invest. 1990, 85, 1150-1157.
92. Gordon, J. Extracellular ATP: effects, sources, and fate. Biochem. J. 1986, 233, 309-319.
93. O'Connor, S. E.; Dainty, I. A.; Leff, P. Further subclassification of ATP receptors based on agonist studies. Trends Pharmacol. Sci. 1991, 12, 137-141.
94. Dubyak, G. R. Signal Transduction by P2-Purinergic Receptors for Extracellular ATP. Am. J. Respir. Cell. Mol. Biol. 1991, 4, 295-300.
95. Forsyth, K. M.; Bjur, R. A.; Westfall, D. P. Nucleotide modulation of norepinephrine release from sympathetic nerves in the rat vas deferens. J. Pharmacol. Exp. Ther. 1991, 256, 821-826.
96. Westfall, D. P.; Shinozuka, K.; Forsyth, K. M.; Bjur, R. A. Modulation of norepinephrine release by ATP and adenosine. In Purines in Cellular Signaling. Targets for New Drugs; Jacobson, K. A., Daly, J. W., Manganiello, V., Eds.; Springer Verlag: New York, 1990; pp 260-265.
97. Hilderman, R. H.; Martin, M.; Zimmerman, J. K.; Pivorun, E. B. Identification of a unique membrane receptor for adenosine 5′, 5‴-P1,P4-tetraphosphate. J. Biol. Chem. 1991, 266, 6915-6918.
98. Burnstock, G. Purinergic mechanisms. Ann. N.Y. Acad. Sci. 1990, 603, 1-17.
99. Rapaport, E. Mechanisms of anticancer activities of adenine nucleotides in tumor-bearing hosts. Ann. N.Y. Acad. Sci. 1990, 603, 142-150.
100. Chaudry, I. H. Use of ATP following shock and ischemia. Ann. N.Y. Acad. Sci. 1990, 603, 130-141.
101. Fredholm, B. B.; Dunwiddie, T. V. How does adenosine inhibit transmitter release? Trends Pharmacol. Sci. 1988, 9, 130-134.
102. Cooper, D. M. F.; Caldwell, K. K. Signal transduction mechanisms for adenosine. In Adenosine and Adenosine Receptors; Williams, M., Ed.; Humana; Clifton, NJ, 1990; pp 105-141.
103. Burnstock, G. Dual control of local blood flow by purines. Ann. N.Y. Acad. Sci. 1990, 603, 31-45.
104. Linden, J.; Prater, M. R.; Sullivan, G. W.; Johns, R. A.; Patel, A. Contamination of adenosine deaminase by superoxide dismutase. Stabilization of endothelium-derived relaxing factor. Biochem. Pharmacol. 1991, 41, 273-279.
105. Stiles, G. A.; Daly, D. T.; Olsson, R. A. The A1 adenosine receptor. Identification of the binding subunit by photoaffinity crosslinking. J. Biol. Chem. 1985, 260, 10806-10811.
106. Choca, J. I.; Kwatra, M. M.; Hosey, M. M.; Green, R. D. Specific photoaffinity labelling of inhibitory adenosine receptors. Biochem. Biophys. Res. Commun. 1985, 131, 115-121.
107. Lohse, M. J.; Klotz, K. N.; Schwabe, U. Agonist photoaffinity labeling of A1 adenosine receptors; persistent activation reveals spare receptors. Mol. Pharmacol. 1986, 30, 403-409.
108. Stiles, G. L.; Jacobson, K. A. A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Mol. Pharmacol. 1987, 32, 184-188.
109. Barrington, W. W.; Jacobson, K. A.; Stiles, G. L. Demonstration of distinct agonist and antagonist conformations of the Ax adenosine receptor. J. Biol. Chem. 1989, 264, 3157-3164.
110. Ji, X. D.; Stiles, G. L.; van Galen, P. J. M.; Jacobson, K. A. Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling. J. Recept. Res. 1992, in press.
111. Nanoff, C.; Jacobson, K. A.; Stiles, G. L. The A2 Adenosine receptor—guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol. Pharmacol. 1991, 39, 130-135.
112. Ramkumar, V.; Barrington, W. W.; Jacobson, K. A.; Stiles, G. L. Demonstration of both At and A2 adenosine receptors in DDTx MF-2 smooth muscle cells. Mol. Pharmacol. 1990, 37, 149-156.
113. Stiles, G. L.; Jacobson, K. A. High affinity acylating antagonists for the Ax adenosine receptor; identification of binding subunit. Mol. Pharmacol. 1988, 34, 724-728.
114. Nakata, H. Purification of Ax adenosine receptor from rat brain membranes. J. Biol. Chem. 1989, 264, 16545-16551.
115. Olah, M. E.; Jacobson, K. A.; Stiles, G. L. Purification and characterization of bovine cerebral cortex Ax adenosine receptor. Arch. Biochem. Biophys. 1990, 283, 440 446.
116. Mahan, L. C.; McVittie, L. D.; Smyk-Randall, E. M.; Nakata, H.; Monsma, F. J.; Gerfen, C. R.; Sibley, D. R. Cloning and expression of an Ax1adenosine receptor from rat brain. Mol. Pharmacol. 1991, 40, 1-7.
117. Reppert, S. M.; Weaver, D. R.; Stehle, J. H.; Rivkees, S. A. Molecular cloning of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol. Endocrinol. 1991, 5, 1037-1048.
118. Klotz, K. N.; Lohse, M. J. The glycoprotein nature of A1 adenosine receptors. Biochem. Biophys. Res. Commun. 1986, 140, 406-413.
119. Stiles, G. L. Photoaffinity cross-linked A, adenosine receptor-binding subunits. Homologous glycoprotein expression by different tissues. J. Biol. Chem. 1986, 261, 10839-10843.
120. Barrington, W. W.; Jacobson, K. A.; Stiles, G. L. Glycoprotein nature of the A2-adenosine receptor binding subunit. Mol. Pharmacol. 1990, 38, 177-183.
121. van Galen, P. J. M.; Stiles, G. L.; Michaels, G. S.; Jacobson, K. A. Adenosine Ax and A2 receptors: structure function relationships. Med. Res. Rev. 1992, in press.
122. O'Dowd, B. F.; Hnatowich, M.; Caron, M. G.; Lefkowtiz, R. J.; Bouvier, M. Palmitoylation of the human β-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor. J. Biol. Chem. 1989, 264, 7564-7569.
123. Ovchinnikov, Y. A.; Abdulaev, N. G.; Bogachuk, A. S. Two adjacent cysteine residues in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitylated. FEBS Lett. 1988, 230, 1-5.
124. Stiles, G. L. Ax adenosine receptor-G protein coupling in bovine brain membranes: effects of guanine nucleotides, salt, and solubilization. J. Neurochem. 1988, 51, 1592-1598.
125. Klotz, K. N.; Lohse, M. J.; Schwabe, U. Chemical modification of Ax adenosine receptors in rat brain membranes. Evidence for histidine in different domains of the ligand binding site. J. Biol. Chem. 1988, 263, 17522-17526.
126. van de Wenden, E. M.; van Galen, P. J. M.; IJzerman, A. P.; Soudijn, W. A model for the hydrogen bonding interactions between adenosine receptor ligands and histidyl residues in the adenosine Ax receptor binding site, based on AMI calculations. J. Comput. Chem. (Theochem) 1991, 231, 175-184.
127. Jarvis, M. F.; Williams, M. Adenosine in central nervous system function. In Adenosine and Adenosine Receptors; Williams, M., Ed.; Humana Press: Clifton, NJ, 1990; pp 423-474.
128. Williams, M. Challenges in the search for CNS therapeutics in the 1990s. Curr. Opinion Therap. Patent 1991, 1, 693-723.
129. Williams, M. Purine nucleosides and nucleotides as central nervous system modulators. Ann. N.Y. Acad. Sci. 1990,603, 93-107.
130. Diamond, I.; Gordon, A. Use of adenosine agonists and antagonists in the treatment of alcohol abuse. Eur. Patent Application 0 431 758 A2, 1991.
131. Heffner, T. G.; Wiley, J. N.; Williams, A. E.; Bruns, R. F.; Coughenour, L. J.; Downs, D. A. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology 1989, 98, 31-37.
132. Dunwiddie, T. V.; Worth, T. Sedative and anticonvulsant actions of adenosine analogs in mouse and rat. J. Pharmacol. Exp. Ther. 1982, 220, 70-76.
133. Dragunow, M.; Goddard, G. V.; Laverty, R. Is adenosine an endogenous anticonvulsant? Epilepsia 1985, 26, 480-487.
134. Evans, M. C.; Swan, J. H.; Meldrum, B. S. An adenosine analogue, 2-chloroadenosine protects against long term development of ischemic cell loss in the rat hippocampus. Neurosci. Lett. 1987, 83, 287-292.
135. Jacobsen, E. J.; McCall, J. M. Acute ischemic and traumatic injury to the CNS. Ann. Rep. Med. Chem. 1990, 25, 31-40.
136. Barone, S.; Churchill, P. C.; Jacobson, K. A. Adenosine receptor prodrugs. Towards kidney selective dialkylxanthines. J. Pharmacol. Exp. Ther. 1989, 250, 79-85.
137. Anderson, W.; Pop, E.; Lee, S.-K.; Bhagrath, M.; Bodor, N.; Brewster, M. Brain-targeting chemical delivery systems for adenosine depresses locomotor behavior in rats. Med. Chem. Res. 1991, 1, 74-79.
138. Shinoda, I.; Furukawa, Y.; Furukawa, S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem. Pharmacol. 1990, 39, 1813-1816.
139. Scrip, Pentoxyfylline for AIDS? Scripta 1610, 1991, 27.
140. Rao, K. M. K.; Currie, M. S.; McCachren, S. S.; Cohen, H. J. Pentoxifylline and other methylxanthines inhibit interleukin- 2 receptor expression in human lymphocytes. Cell. Immunol. 1991, 135, 314-325.
141. Polmar, S. H.; Fernadez-Mejia, C.; Birch, R. E. Adenosine receptors: immunologic aspects. In Adenosine Receptors; Cooper, D. M. F., Londos, C., Eds.; Liss: New York, 1988; pp 97-112.
142. Green, P. G.; Basbaum, A. I.; Helms, C.; Levine, J. D. Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 4162-4165.
143. Herbert, K. E.; Bhusate, L. L.; Scott, D. L.; Perett, D. Purine metabolism in arthritis: 1. Synovial fluid adenosine concentrations are low in rheumatoid arthritis. Intern. J. Purine Pyrimidine Res. 1991, 2, 31-34.
144. Scaccianoce, S.; Navarra, D.; Di Sciullo, A.; Angelucci, L.; Endroczi, E. Adenosine and pituitary-adrenocortical axis activity in the rat. Neuroendocrinology 1989, 50, 464-468.
145. Herbert, K. E.; Bhusate, L. L.; Scott, D. L.; Perett, D. Purine metabolism in arthritis: 1. Synovial fluid adenosine concentrations are low in rheumatoid arthritis. Intern. J. Purine Pyrimidine Res. 1991, 2, 31-34.
146. Kinzer, D.; Lehmann, V. Extracellular ATP and adenosine modulate tumor necrosis factor-induced lysis of L929 cells in the presence of actinomycin D. J. Immunol. 1991, 146, 2708-2711.
147. Sills, M. A.; Webb, R. L.; Hummel, H.; Francis, J. E.; Stone, G. A. Chronic administration of the adenosine A2-selective agonists, CGS 21680C and CGS 22989, produces receptor down-regulation and tolerance to their hypotensive effects. Pharmacologist 1991, 33, 176.
148. Engler, R. L. Adenosine: the signal of life? Circulation 1991, 84, 951-954.
149. Williams, M. Purinergic receptors as drug targets. Drug News Persp. 1990, 4, 5-12.
150. McMillian, M. K.; Soltoff, S. P.; Cantley, L. C.; Talamo, B. R. Extracellular ATP increases free cytosolic calcium in rat parotid acinar cells. Biochem. J. 1988, 255, 291-300.
151. Soltoff, S. P.; McMillian, M. K.; Talamao, B. R. Coomassie brilliant blue G is a more potent antagonist of P2 purinergic responses than reactive blue 2 (Cibacron Blue 3GA) in rate parotid acinar cells. Biochem. Biophys. Res. Commun. 1989, 165, 1279-1285.
152. Bruns, R. F. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can. J. Physiol. Pharmacol. 1980, 58, 673-691.
153. Lohse, M. J.; Böser, S.; Klotz, K. N.; Schwabe, U. Affinities of barbiturates for the GABA-receptor complex and A, adenosine receptors: a possible explanation of their excitatory effects. Naunyn Schmiedeberg’s Arch. Pharmacol. 1987 336 211—217.
154. Daly, J. W.; Hong, O.; Padgett, W. L.; Shamim, M. T.; Jacobson, K. A.; Ukena, D. Non-xanthine heterocycles: activity as antagonists of Ax- and A2-adenosine receptors. Biochem. Pharmacol. 1988, 37, 655-664.
155. Peet, N. P.; Dickerson, G. A.; Abdallah, A. H.; Daly, J. W.; Ukena, D. Benzo[l,2-c:5,4-c]dipyrazoles: non-xanthine adenosine antagonists. J. Med. Chem. 1988, 31, 2034-2039.
156. Skerrit, J. H.; Davies, L. P.; Johnston, G. A. R. A purinergic component in the anticonvulsant action of carbamazepine? Eur. J. Pharmacol. 1982, 82, 195-197.
157. Daly, J. W.; Hide, I.; Bridson, P. K. Imidazodiazepinediones: a new class of adenosine receptor antagonists. J. Med. Chem. 1990, 33, 2818-2821.
158. Psychoyos, S.; Ford, C. J.; Phillips, M. A. Inhibition by etazolate (SQ 20009) and cartazolate (SQ 65396) of adenosinestimulated [3H]cAMP formation in 2-[3H]adenine-prelabeled vesicles prepared from guinea pig cerebral cortex. Biochem. Pharmacol. 1982, 31, 1441-1442.
159. Davies, L. P.; Chow, S. C.; Skerrit, J. H.; Brown, D. J.; Johnston, G. A. R. Pyrazolo[3,4-d]pyTimidines as adenosine antagonists. Life Sci. 1984, 34, 2117-2128.
160. Hamilton, H. W.; Ortwine, D. F.; Worth, D. F.; Bristol, J. A. Synthesis and structure-activity relationships of pyrazolo- [4,3-d]pyrimidin-7-ones as adenosine receptor antagonists. J. Med. Chem. 1987, 30, 91-96.
161. Garritsen, A.; IJzerman, A. P.; Beukers, M. W.; Cragoe, E. J.; Soudijn, W. Interaction of amiloride and its analogues with adenosine A! receptors in calf brain. Biochem. Pharmacol. 1990, 40, 827-834.
162. van Galen, P. J. M.; IJzerman, A. P.; Soudijn, W. Xanthine- 7-ribosides as adenosine receptor antagonists. Nucleoside Nucleotide 1990, 9, 275-291.
163. Knowles, M.; Lane, L. C.; Boucher, R. C. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. New Eng. J. Med. 1991, 325, 533-538.
164. Thompson, R. D.; Secunda, S.; Daly, J. W.; Olsson, R. A. Activity of N6-substituted 2-chloroadenosines at At and A2-adenosine receptors. J. Med. Chem. 1991, 34, 3388-3390.
165. Jacobson, K. A.; Stiles, G. L.; Ji, X. D. J. Biol. Chem. Chemical modification and irreversible inhibition of striated A2a-adenosine receptors. Mol. Pharmacol. 1992, submitted.
166. Yoon, K.-W.; Rothman, S. M. Adenosine inhibits excitatory but not inhibitory synaptic transmission in the hippocampus. J. Neurosci. 1991, 11, 1375-1380.
167. Jacobson, K. A. Adenosine (P2) and ATP (P2) receptors. Comp. Med. Chem. 1990, 3, 601-642.
168. Eidelman, O.; Guay-Broder, C.; van Galen, P. J. M.; Jacobson, K. A.; Fox, C.; Turner, R. J.; Cabantchile, Z. I.; Pollard, H. B. A1-Adenosine antagonist drugs activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. Sci. U.S.A. 1992, in press.
169. Jacobson, K. A. Adenosine (P2) and ATP (P2) receptors. Comp. Med. Chem. 1990, 3, 601-642.
170. Sykes, R. Comments. F.D.C. Reports 1991, 53 (50), 20.
171. Honore, E.; Fournier, F.; Collin, T.; Nargeot, T.; Guilbault, P. Functional expression of Pzy purinoceptor in Xenopus oocyte injected with brain mRNA. Pflugen Arch. 1991, 418, 447-452.